Overview
- The Fundación Instituto Leloir team published results in Molecular Therapy: Oncology describing AR2015, an engineered adenovirus aimed at colorectal and other gastrointestinal tumors.
- AR2015’s replication is driven by a hybrid tumor‑specific promoter built from A33 and vWA2 gene fragments selected through bioinformatics and artificial intelligence to address tumor heterogeneity.
- In laboratory and animal studies, intravenous AR2015 replicated in malignant cells without harming healthy tissue and reduced or eliminated liver metastases, with stronger effects when paired with low‑dose chemotherapy.
- In patient‑derived colorectal tumor samples, at least one of the two target genes was active across all primary tumors and metastases analyzed, supporting the virus’s selective activity.
- The investigators have filed an international patent and are pursuing financing to complete required preclinical work before seeking regulatory clearance for clinical trials, and human safety and efficacy remain unproven.